Tofacitinib was the first oral JAK inhibitor to transform the treatment of inflammatory disease but after the ORAL Surveillance trial, its boxed warning reshaped how many clinicians viewed the entire class.

Now, everything is changing again.

With generic tofacitinib becoming dramatically less expensive, clinicians are asking whether it’s time to take another look. In this episode of Skin in the Game, Drs. Diego Ruiz Dasilva and Graham Litchman unpack the history of tofacitinib, what the boxed warning actually means, how to interpret the available safety data, and where the drug may still have an important role in dermatology.

Whether you’re excited about the affordability of generic JAK inhibitors or remain cautious because of the boxed warning, this episode explores the evidence behind the headlines.

Skin in the Game delivers high-yield dermatology quick hits for busy clinicians.

Hosted by:
• Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV
• Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia Beach, VA

We read the research so you don’t have to.

For show notes and more information please visit our website at https://skininthegamepodcast.buzzsprout.com/

Disclaimer: This podcast is intended for educational purposes only and does not constitute medical advice. Views expressed are those of the hosts and do not necessarily reflect those of their employers or affiliated organizations.